Education
About Us
Working with TipRanks
Follow Us
Theralase Technologies (TSE:TLT)
:TLT
RESEARCH TOOLSreports
Total Valuation
Theralase Technologies has a market cap or net worth of C$48.91M. The enterprise value is C$36.79M.
Market CapC$48.91M
Enterprise ValueC$36.79M
Share Statistics
Theralase Technologies has 250,810,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding250,810,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Theralase Technologies’s return on equity (ROE) is -2.06 and return on invested capital (ROIC) is -181.61%.
Return on Equity (ROE)-2.06
Return on Assets (ROA)-1.31
Return on Invested Capital (ROIC)-181.61%
Return on Capital Employed (ROCE)-1.90
Revenue Per Employee73.82K
Profits Per Employee-304.01K
Employee Count14
Asset Turnover0.32
Inventory Turnover0.88
Valuation Ratios
The current PE Ratio of Theralase Technologies is -14.95. Theralase Technologies’s PEG ratio is -0.76.
PE Ratio-14.95
PS Ratio0.00
PB Ratio21.51
Price to Fair Value30.77
Price to FCF-12.79
Price to Operating Cash Flow-12.96
PEG Ratio-0.76
Income Statement
In the last 12 months, Theralase Technologies had revenue of 1.03M and earned -4.26M in profits. Earnings per share was -0.02.
Revenue1.03M
Gross Profit554.03K
Operating Income-4.29M
Pretax Income-4.26M
Net Income-4.26M
EBITDA-3.96M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -3.33M and capital expenditures -19.97K, giving a free cash flow of -3.35M billion.
Operating Cash Flow-3.33M
Free Cash Flow-3.35M
Free Cash Flow per Share-0.01
Dividends & Yields
Theralase Technologies pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.19
52-Week Price Change0.00%
50-Day Moving Average0.19
200-Day Moving Average0.23
Relative Strength Index (RSI)58.69
Average Volume (3m)59.78K
Important Dates
Theralase Technologies upcoming earnings date is Sep 1, 2025, TBA Not Confirmed.
Last Earnings DateMay 29, 2025
Next Earnings DateSep 1, 2025
Ex-Dividend Date―
Financial Position
Theralase Technologies as a current ratio of 1.61, with Debt / Equity ratio of 15.31%
Current Ratio1.61
Quick Ratio1.05
Debt to Market Cap0.00
Net Debt to EBITDA>-0.01
Interest Coverage Ratio-177.68
Taxes
In the past 12 months, Theralase Technologies has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Theralase Technologies EV to EBITDA ratio is -16.07, with an EV/FCF ratio of -19.02.
EV to Sales61.58
EV to EBITDA-16.07
EV to Free Cash Flow-19.02
EV to Operating Cash Flow-19.13
Balance Sheet
Theralase Technologies has C$268.76K in cash and marketable securities with C$293.87K in debt, giving a net cash position of C$25.11K billion.
Cash & Marketable SecuritiesC$268.76K
Total DebtC$293.87K
Net CashC$25.11K
Net Cash Per Share<C$0.01
Tangible Book Value Per Share<C$0.01
Margins
Gross margin is 55.17%, with operating margin of -414.96%, and net profit margin of -411.84%.
Gross Margin55.17%
Operating Margin-414.96%
Pretax Margin-411.84%
Net Profit Margin-411.84%
EBITDA Margin-383.18%
EBIT Margin-409.51%
Analyst Forecast
The average price target for Theralase Technologies is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-8.63%
EPS Growth Forecast7.04%